Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?

Mohammad Javad Hajipour; Hossein Mohammad-Beigi; Iraj Nabipour; Negar Mahmoudi; Morteza Azhdarzadeh; Hossein Derakhshankhah; Dina El Dawud; Reza Mohammadinejad; Daniel Otzen

doi:10.1016/j.nantod.2020.100983

Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?

Mohammad Javad Hajipour^*, Hossein Mohammad-Beigi, Iraj Nabipour, Negar Mahmoudi, Morteza Azhdarzadeh, Hossein Derakhshankhah, Dina El Dawud, Reza Mohammadinejad, Daniel Otzen

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.

Originalsprog	Engelsk
Artikelnummer	100983
Tidsskrift	Nano Today
Vol/bind	35
Nummer	December
Antal sider	5
ISSN	1748-0132
DOI	https://doi.org/10.1016/j.nantod.2020.100983
Status	Udgivet - 2020

Adgang til dokumentet

10.1016/j.nantod.2020.100983

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{f0cde5a146994241bdb03882cccbe7b0,

title = "Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?",

abstract = "Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.",

keywords = "Alzheimer's disease, Aβ, Fibrillation, Nanoparticles, Nanotechnology",

author = "Hajipour, {Mohammad Javad} and Hossein Mohammad-Beigi and Iraj Nabipour and Negar Mahmoudi and Morteza Azhdarzadeh and Hossein Derakhshankhah and {El Dawud}, Dina and Reza Mohammadinejad and Daniel Otzen",

year = "2020",

doi = "10.1016/j.nantod.2020.100983",

language = "English",

volume = "35",

journal = "Nano Today",

issn = "1748-0132",

publisher = "Elsevier Ltd",

number = "December",

}

Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction? / Hajipour, Mohammad Javad; Mohammad-Beigi, Hossein; Nabipour, Iraj et al.
I: Nano Today, Bind 35, Nr. December, 100983, 2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Amyloid fibril inhibition, acceleration, or fragmentation

T2 - Are nano-based approaches advance in the right direction?

AU - Hajipour, Mohammad Javad

AU - Mohammad-Beigi, Hossein

AU - Nabipour, Iraj

AU - Mahmoudi, Negar

AU - Azhdarzadeh, Morteza

AU - Derakhshankhah, Hossein

AU - El Dawud, Dina

AU - Mohammadinejad, Reza

AU - Otzen, Daniel

PY - 2020

Y1 - 2020

N2 - Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.

AB - Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.

KW - Alzheimer's disease

KW - Aβ

KW - Fibrillation

KW - Nanoparticles

KW - Nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=85091740646&partnerID=8YFLogxK

U2 - 10.1016/j.nantod.2020.100983

DO - 10.1016/j.nantod.2020.100983

M3 - Journal article

SN - 1748-0132

VL - 35

JO - Nano Today

JF - Nano Today

IS - December

M1 - 100983

ER -

Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater